Latest news
{{'2026-02-23T09:33:18Z' | dateFormatFilter}}
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
{{'2026-02-20T12:02:49Z' | dateFormatFilter}}
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
{{'2026-02-17T13:58:25Z' | dateFormatFilter}}
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
